Eyepoint (EYPT) closed at $0.31 on November 16, 2026, up 0.5% from the previous close, on volume of 5,990,657 shares (30-day average 13,145,461).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts | Position |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Guggenheim Sticks to Their Hold Rating for EyePoint Pharmaceuticals (EYPT)
TipRanks (Mon, 16-Nov 8:15 AM ET)
EyePoint Pharma Earnings Call: DME Focus After Wet AMD Setback
TipRanks (Sat, 14-Nov 11:58 PM ET)
TipRanks (Fri, 13-Nov 9:40 AM ET)
RBC Capital Remains a Hold on EyePoint Pharmaceuticals (EYPT)
TipRanks (Fri, 13-Nov 9:37 AM ET)
EyePoint Pharmaceuticals GAAP EPS of -$1.07 misses by $0.15, revenue of $0.8M beats by $0.57M
Seeking Alpha News (Thu, 12-Nov 7:06 AM ET)
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
Globe Newswire (Thu, 12-Nov 7:00 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
EyePoint Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 11:01 AM ET)
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
Globe Newswire (Fri, 6-Nov 7:00 AM ET)
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Eyepoint trades on the NASDAQ stock market under the symbol EYPT.
As of November 16, 2026, EYPT stock price was flat at $0.31 with 5,990,657 million shares trading.
EYPT has a beta of 3.71, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.04 to the broad based SPY ETF.
EYPT has a market cap of $35.00 million. This is considered a Sub-Micro Cap stock.
Last quarter Eyepoint reported $756,000 in Revenue and -$1.07 earnings per share. This beat revenue expectation by $529,536 and missed earnings estimates by -$.15.
In the last 3 years, EYPT traded as high as $30.99 and as low as $.28.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, VXF, VTWO, IWM, VHT.
EYPT has underperformed the market in the last year with a price return of -97.3% while the SPY ETF gained +11.2%. EYPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -97.7% and -11.7%, respectively, while the SPY returned -4.6% and -2.1%, respectively.
EYPT support price is $.29 and resistance is $.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.